Loading…
The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma
Background The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after repe...
Saved in:
| Published in: | Cancer medicine (Malden, MA) MA), 2021-08, Vol.10 (16), p.5466-5474 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c6422-a44f219ecb365a184d85648bfc49eaacca67893db170db72682671802b2f43d73 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c6422-a44f219ecb365a184d85648bfc49eaacca67893db170db72682671802b2f43d73 |
| container_end_page | 5474 |
| container_issue | 16 |
| container_start_page | 5466 |
| container_title | Cancer medicine (Malden, MA) |
| container_volume | 10 |
| creator | Chen, Zhi‐Yuan Guo, Zhi‐Xing Lu, Liang‐He Mei, Jie Lin, Wen‐Ping Li, Shao‐Hua Wei, Wei Guo, Rong‐Ping |
| description | Background
The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after repeat hepatic resection (RHR) or radiofrequency ablation (RFA).
Methods
From December 2005 to December 2016, 138 patients receiving RHR and 188 patients receiving RFA were recruited. VETC was evaluated by immunohistochemical staining for CD34. The survival outcomes of patients with VETC pattern or not were investigated.
Results
There was no significant difference between the RHR and RFA groups in disease‐free survival (DFS) or overall survival (OS) as determined by the univariate analysis of the whole cohort. In the subgroup analysis of the VETC‐positive cohort, the patients in the RHR group showed a longer median DFS time in contrast to those in the RFA group (15.0 vs. 5.0 months, p = 0.001). Similarly, the patients in the RHR group showed a longer median OS time in contrast to those in the RFA group (39.5 vs. 19 months, p = 0.001). In the VETC‐negative cohort, no significant differences in DFS and OS rates between the RHR and RFA groups were observed (p > 0.05).
Conclusions
The results of our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting HCC patients who may benefit from RHR.
Our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting |
| doi_str_mv | 10.1002/cam4.4102 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d3350087e794466caccb10dfa34cb910</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d3350087e794466caccb10dfa34cb910</doaj_id><sourcerecordid>2561422383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6422-a44f219ecb365a184d85648bfc49eaacca67893db170db72682671802b2f43d73</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhiMEotXSA38AWeICh239FSd7QapWfFQq4lLO1sSZ7Lpy4mA7Wy0n7lz4jfwSnG6pWiR8seV59Ghm9BbFS0ZPGaX8zEAvTyWj_ElxzKksl5US8umD91FxEuM1zaeiXFXseXEkJGe85NVx8fNqi2QM2FqT7A7JDtyExHdkhzGiiwQHA2OcHCQ7bEiaeh-IcVNMGCKxA0kBIfU4JOLHZHv7PYN-IF3GApophLmEENz-949fMcEGyRZHSN6gc1mbbRCMHXwPL4pnHbiIJ3f3ovj64f3V-tPy8svHi_X55dIoyfkSpOw4W6FphCqB1bKtSyXrpjNyhQDGgKrqlWgbVtG2qbiq56lryhveSdFWYlFcHLyth2s9BttD2GsPVt9--LDREJI1DnUrRElpXWG1klIpk-0No20HQppmxWh2vTu4xqnpsTV52gDukfRxZbBbvfE7XQulaG5zUby5EwT_bcKYdG_jvBsY0E9R81LWkpVCyIy-_ge99lMY8qoypVjejahFpt4eKBN8jAG7-2YY1XNi9JwYPScms68edn9P_s1HBs4OwI11uP-_Sa_PP8tb5R-Q686r</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2561422383</pqid></control><display><type>article</type><title>The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma</title><source>Open Access: PubMed Central</source><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>Publicly Available Content (ProQuest)</source><creator>Chen, Zhi‐Yuan ; Guo, Zhi‐Xing ; Lu, Liang‐He ; Mei, Jie ; Lin, Wen‐Ping ; Li, Shao‐Hua ; Wei, Wei ; Guo, Rong‐Ping</creator><creatorcontrib>Chen, Zhi‐Yuan ; Guo, Zhi‐Xing ; Lu, Liang‐He ; Mei, Jie ; Lin, Wen‐Ping ; Li, Shao‐Hua ; Wei, Wei ; Guo, Rong‐Ping</creatorcontrib><description>Background
The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after repeat hepatic resection (RHR) or radiofrequency ablation (RFA).
Methods
From December 2005 to December 2016, 138 patients receiving RHR and 188 patients receiving RFA were recruited. VETC was evaluated by immunohistochemical staining for CD34. The survival outcomes of patients with VETC pattern or not were investigated.
Results
There was no significant difference between the RHR and RFA groups in disease‐free survival (DFS) or overall survival (OS) as determined by the univariate analysis of the whole cohort. In the subgroup analysis of the VETC‐positive cohort, the patients in the RHR group showed a longer median DFS time in contrast to those in the RFA group (15.0 vs. 5.0 months, p = 0.001). Similarly, the patients in the RHR group showed a longer median OS time in contrast to those in the RFA group (39.5 vs. 19 months, p = 0.001). In the VETC‐negative cohort, no significant differences in DFS and OS rates between the RHR and RFA groups were observed (p > 0.05).
Conclusions
The results of our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting HCC patients who may benefit from RHR.
Our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting</description><identifier>ISSN: 2045-7634</identifier><identifier>EISSN: 2045-7634</identifier><identifier>DOI: 10.1002/cam4.4102</identifier><identifier>PMID: 34212527</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Adult ; Carcinoma, Hepatocellular - blood supply ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - surgery ; CD34 antigen ; Clinical Cancer Research ; Disease-Free Survival ; Female ; Follow-Up Studies ; Hepatectomy ; Hepatectomy - statistics & numerical data ; Hepatocellular carcinoma ; Humans ; Liver - blood supply ; Liver - pathology ; Liver - surgery ; Liver cancer ; Liver Neoplasms - blood supply ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - surgery ; Male ; Medical prognosis ; Metastasis ; Middle Aged ; Neoplasm Recurrence, Local - blood supply ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - surgery ; Neoplasm Staging ; Patients ; Prognosis ; radiofrequency ablation ; Radiofrequency Ablation - statistics & numerical data ; repeat hepatic resection ; Retrospective Studies ; Survival ; Survival Rate ; Tumors ; vessels encapsulating tumor cluster</subject><ispartof>Cancer medicine (Malden, MA), 2021-08, Vol.10 (16), p.5466-5474</ispartof><rights>2021 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6422-a44f219ecb365a184d85648bfc49eaacca67893db170db72682671802b2f43d73</citedby><cites>FETCH-LOGICAL-c6422-a44f219ecb365a184d85648bfc49eaacca67893db170db72682671802b2f43d73</cites><orcidid>0000-0003-2799-3463</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2561422383/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2561422383?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34212527$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Zhi‐Yuan</creatorcontrib><creatorcontrib>Guo, Zhi‐Xing</creatorcontrib><creatorcontrib>Lu, Liang‐He</creatorcontrib><creatorcontrib>Mei, Jie</creatorcontrib><creatorcontrib>Lin, Wen‐Ping</creatorcontrib><creatorcontrib>Li, Shao‐Hua</creatorcontrib><creatorcontrib>Wei, Wei</creatorcontrib><creatorcontrib>Guo, Rong‐Ping</creatorcontrib><title>The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma</title><title>Cancer medicine (Malden, MA)</title><addtitle>Cancer Med</addtitle><description>Background
The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after repeat hepatic resection (RHR) or radiofrequency ablation (RFA).
Methods
From December 2005 to December 2016, 138 patients receiving RHR and 188 patients receiving RFA were recruited. VETC was evaluated by immunohistochemical staining for CD34. The survival outcomes of patients with VETC pattern or not were investigated.
Results
There was no significant difference between the RHR and RFA groups in disease‐free survival (DFS) or overall survival (OS) as determined by the univariate analysis of the whole cohort. In the subgroup analysis of the VETC‐positive cohort, the patients in the RHR group showed a longer median DFS time in contrast to those in the RFA group (15.0 vs. 5.0 months, p = 0.001). Similarly, the patients in the RHR group showed a longer median OS time in contrast to those in the RFA group (39.5 vs. 19 months, p = 0.001). In the VETC‐negative cohort, no significant differences in DFS and OS rates between the RHR and RFA groups were observed (p > 0.05).
Conclusions
The results of our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting HCC patients who may benefit from RHR.
Our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting</description><subject>Adult</subject><subject>Carcinoma, Hepatocellular - blood supply</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>CD34 antigen</subject><subject>Clinical Cancer Research</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hepatectomy</subject><subject>Hepatectomy - statistics & numerical data</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver - blood supply</subject><subject>Liver - pathology</subject><subject>Liver - surgery</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - blood supply</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - surgery</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - blood supply</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>Neoplasm Staging</subject><subject>Patients</subject><subject>Prognosis</subject><subject>radiofrequency ablation</subject><subject>Radiofrequency Ablation - statistics & numerical data</subject><subject>repeat hepatic resection</subject><subject>Retrospective Studies</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>vessels encapsulating tumor cluster</subject><issn>2045-7634</issn><issn>2045-7634</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kk1v1DAQhiMEotXSA38AWeICh239FSd7QapWfFQq4lLO1sSZ7Lpy4mA7Wy0n7lz4jfwSnG6pWiR8seV59Ghm9BbFS0ZPGaX8zEAvTyWj_ElxzKksl5US8umD91FxEuM1zaeiXFXseXEkJGe85NVx8fNqi2QM2FqT7A7JDtyExHdkhzGiiwQHA2OcHCQ7bEiaeh-IcVNMGCKxA0kBIfU4JOLHZHv7PYN-IF3GApophLmEENz-949fMcEGyRZHSN6gc1mbbRCMHXwPL4pnHbiIJ3f3ovj64f3V-tPy8svHi_X55dIoyfkSpOw4W6FphCqB1bKtSyXrpjNyhQDGgKrqlWgbVtG2qbiq56lryhveSdFWYlFcHLyth2s9BttD2GsPVt9--LDREJI1DnUrRElpXWG1klIpk-0No20HQppmxWh2vTu4xqnpsTV52gDukfRxZbBbvfE7XQulaG5zUby5EwT_bcKYdG_jvBsY0E9R81LWkpVCyIy-_ge99lMY8qoypVjejahFpt4eKBN8jAG7-2YY1XNi9JwYPScms68edn9P_s1HBs4OwI11uP-_Sa_PP8tb5R-Q686r</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Chen, Zhi‐Yuan</creator><creator>Guo, Zhi‐Xing</creator><creator>Lu, Liang‐He</creator><creator>Mei, Jie</creator><creator>Lin, Wen‐Ping</creator><creator>Li, Shao‐Hua</creator><creator>Wei, Wei</creator><creator>Guo, Rong‐Ping</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2799-3463</orcidid></search><sort><creationdate>202108</creationdate><title>The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma</title><author>Chen, Zhi‐Yuan ; Guo, Zhi‐Xing ; Lu, Liang‐He ; Mei, Jie ; Lin, Wen‐Ping ; Li, Shao‐Hua ; Wei, Wei ; Guo, Rong‐Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6422-a44f219ecb365a184d85648bfc49eaacca67893db170db72682671802b2f43d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Carcinoma, Hepatocellular - blood supply</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>CD34 antigen</topic><topic>Clinical Cancer Research</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hepatectomy</topic><topic>Hepatectomy - statistics & numerical data</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver - blood supply</topic><topic>Liver - pathology</topic><topic>Liver - surgery</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - blood supply</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - surgery</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - blood supply</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>Neoplasm Staging</topic><topic>Patients</topic><topic>Prognosis</topic><topic>radiofrequency ablation</topic><topic>Radiofrequency Ablation - statistics & numerical data</topic><topic>repeat hepatic resection</topic><topic>Retrospective Studies</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>vessels encapsulating tumor cluster</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Zhi‐Yuan</creatorcontrib><creatorcontrib>Guo, Zhi‐Xing</creatorcontrib><creatorcontrib>Lu, Liang‐He</creatorcontrib><creatorcontrib>Mei, Jie</creatorcontrib><creatorcontrib>Lin, Wen‐Ping</creatorcontrib><creatorcontrib>Li, Shao‐Hua</creatorcontrib><creatorcontrib>Wei, Wei</creatorcontrib><creatorcontrib>Guo, Rong‐Ping</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley Online Library</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Biological Science Journals</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Cancer medicine (Malden, MA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Zhi‐Yuan</au><au>Guo, Zhi‐Xing</au><au>Lu, Liang‐He</au><au>Mei, Jie</au><au>Lin, Wen‐Ping</au><au>Li, Shao‐Hua</au><au>Wei, Wei</au><au>Guo, Rong‐Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma</atitle><jtitle>Cancer medicine (Malden, MA)</jtitle><addtitle>Cancer Med</addtitle><date>2021-08</date><risdate>2021</risdate><volume>10</volume><issue>16</issue><spage>5466</spage><epage>5474</epage><pages>5466-5474</pages><issn>2045-7634</issn><eissn>2045-7634</eissn><abstract>Background
The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early‐stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early‐stage HCC after repeat hepatic resection (RHR) or radiofrequency ablation (RFA).
Methods
From December 2005 to December 2016, 138 patients receiving RHR and 188 patients receiving RFA were recruited. VETC was evaluated by immunohistochemical staining for CD34. The survival outcomes of patients with VETC pattern or not were investigated.
Results
There was no significant difference between the RHR and RFA groups in disease‐free survival (DFS) or overall survival (OS) as determined by the univariate analysis of the whole cohort. In the subgroup analysis of the VETC‐positive cohort, the patients in the RHR group showed a longer median DFS time in contrast to those in the RFA group (15.0 vs. 5.0 months, p = 0.001). Similarly, the patients in the RHR group showed a longer median OS time in contrast to those in the RFA group (39.5 vs. 19 months, p = 0.001). In the VETC‐negative cohort, no significant differences in DFS and OS rates between the RHR and RFA groups were observed (p > 0.05).
Conclusions
The results of our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting HCC patients who may benefit from RHR.
Our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early‐stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>34212527</pmid><doi>10.1002/cam4.4102</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2799-3463</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-7634 |
| ispartof | Cancer medicine (Malden, MA), 2021-08, Vol.10 (16), p.5466-5474 |
| issn | 2045-7634 2045-7634 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_d3350087e794466caccb10dfa34cb910 |
| source | Open Access: PubMed Central; Open Access: Wiley-Blackwell Open Access Journals; Publicly Available Content (ProQuest) |
| subjects | Adult Carcinoma, Hepatocellular - blood supply Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery CD34 antigen Clinical Cancer Research Disease-Free Survival Female Follow-Up Studies Hepatectomy Hepatectomy - statistics & numerical data Hepatocellular carcinoma Humans Liver - blood supply Liver - pathology Liver - surgery Liver cancer Liver Neoplasms - blood supply Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - surgery Male Medical prognosis Metastasis Middle Aged Neoplasm Recurrence, Local - blood supply Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - surgery Neoplasm Staging Patients Prognosis radiofrequency ablation Radiofrequency Ablation - statistics & numerical data repeat hepatic resection Retrospective Studies Survival Survival Rate Tumors vessels encapsulating tumor cluster |
| title | The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early‐stage hepatocellular carcinoma |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A57%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20predictive%20value%20of%20vessels%20encapsulating%20tumor%20clusters%20in%20treatment%20optimization%20for%20recurrent%20early%E2%80%90stage%20hepatocellular%20carcinoma&rft.jtitle=Cancer%20medicine%20(Malden,%20MA)&rft.au=Chen,%20Zhi%E2%80%90Yuan&rft.date=2021-08&rft.volume=10&rft.issue=16&rft.spage=5466&rft.epage=5474&rft.pages=5466-5474&rft.issn=2045-7634&rft.eissn=2045-7634&rft_id=info:doi/10.1002/cam4.4102&rft_dat=%3Cproquest_doaj_%3E2561422383%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c6422-a44f219ecb365a184d85648bfc49eaacca67893db170db72682671802b2f43d73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2561422383&rft_id=info:pmid/34212527&rfr_iscdi=true |